# hVIVO Services

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hvivo-services

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.hvivo.com/
- Total disclosed funding: $6M
- Latest round: Series B (Oct 8, 2009)
- Investors on record: 2

## About

hVIVO Services Limited, based in the UK, specializes in human challenge clinical trials, offering innovative solutions for testing vaccines and therapeutics to combat infectious and respiratory diseases.Founded in 1989 in London, UK, hVIVO Services Limited conducts human challenge studies that allow for the evaluation of vaccines and therapeutics. The company has participated in 4 deals and recently completed an IPO, raising GBP 15.00 mn, which is the total amount raised to date. Cathal Friel is the founder, who has also been involved in other ventures in the biopharmaceutical space.hVIVO provides specialized contract research services focused on human challenge clinical trials for various pathogens. The company’s offerings include validated human challenge models for respiratory syncytial virus (RSV), seasonal influenza, COVID-19, human metapneumovirus (hMPV), human rhinoviruses (HRV), and malaria. These models enable clients in the pharmaceutical, biotechnology, and academic sectors to assess the efficacy and safety of their products under controlled conditions. hVIVO has extensive experience, having conducted trials for over 15 years and serving clients across North America, Europe, and Asia.In the most recent year of 2023, hVIVO reported a revenue of GBP 60,059,676.20 and an EBITDA of GBP 17,097,888.40. Revenue is primarily generated from clinical trial services provided through contracts with pharmaceutical companies, research institutions, and government agencies.hVIVO aims to enhance its product offerings and expand its market reach. The company is focused on developing new human challenge models to adapt to emerging infectious diseases and anticipates launching these products over the next 12 months. Additionally, hVIVO plans to penetrate new markets in Asia and North America by 2025. The recent IPO and the GBP 15.00 mn raised will support these growth initiatives, particularly in expanding research and development capabilities.

## Funding rounds

- Series B, Oct 8, 2009, $4.2M — Aquarius Equity Partners, Longview Innovation
- Series A, Aug 23, 2006, $1.9M — Longview Innovation

## Investors

- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series A, Series B
- Aquarius Equity Partners (https://capitalatlas.ai/funds/aquarius-equity-partners) — Series B